Ignite Creation Date:
2024-07-17 @ 12:05 PM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06469281
Status:
RECRUITING
Last Update Posted:
2024-06-21
First Post:
2024-06-06
Brief Title:
A Study to Learn if 27T51 a Mucin-16 MUC16 Protein Targeting Immune Cell Therapy Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
Sponsor:
Regeneron Pharmaceuticals
Organization:
Regeneron Pharmaceuticals
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-06-28
Start Date Type:
ESTIMATED
Primary Completion Date:
2028-07-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-06-29
Completion Date Type:
ESTIMATED
First Submit Date:
2024-06-06
First Submit QC Date:
None
Study First Post Date:
2024-06-21
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-08-06
Last Update Post Date:
2024-06-21
Last Update Post Date Type:
ACTUAL